Insider Shareholders with Direct Ownership of Kiniksa Pharmaceuticals, Ltd. (KNSA)
This section provides a comprehensive overview of the insiders with direct ownership of Kiniksa Pharmaceuticals, Ltd. (KNSA). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Kiniksa Pharmaceuticals, Ltd. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Thomas W. Beetham
EVP & Chief Legal Officer |
300,000 | 2,477 | 297,523 $5.55 Million | 2 |
Feb 03, 2021
Reduced 0.83%
|
|
Eben Tessari
CHIEF OPERATING OFFICER |
28,944 | 8,862 | 126,024 $2.35 Million | 25 |
Apr 08, 2024
Reduced 0.63%
|
|
Sanj K Patel
CHAIRMAN & CEO |
271,788 | 208,776 | 63,012 $1.18 Million | 30 |
Apr 08, 2024
Reduced 6.07%
|
|
John F. Paolini
CHIEF MEDICAL OFFICER |
140,721 | 122,918 | 47,803 $892,482 | 32 |
Apr 08, 2024
Reduced 1.51%
|
|
Michael R Megna
CHIEF ACCOUNTING OFFICER |
68,827 | 48,636 | 21,328 $398,193 | 40 |
Apr 08, 2024
Reduced 7.25%
|
|
Mark Ragosa
CHIEF FINANCIAL OFFICER |
39,853 | 20,600 | 19,253 $359,453 | 30 |
Apr 26, 2024
Reduced 2.58%
|
|
Ross Moat
CHIEF COMMERCIAL OFFICER |
22,433 | 9,539 | 16,276 $303,872 | 25 |
Apr 08, 2024
Reduced 7.67%
|
| 29,680 | 0 | 14,840 $277,062 | 1 |
Jun 06, 2019
Added 50.0%
|
|
| 12,897 | 0 | 12,897 $240,786 | 4 |
Jun 06, 2024
Added 25.32%
|
|
| 9,373 | 0 | 9,373 $174,993 | 2 |
Jun 06, 2024
Added 31.81%
|
|
| 31,332 | 21,959 | 9,373 $174,993 | 4 |
Jun 06, 2024
Added 31.81%
|
|
| 9,373 | 0 | 9,373 $174,993 | 2 |
Jun 06, 2024
Added 31.81%
|
|
| 9,373 | 0 | 9,373 $174,993 | 2 |
Jun 06, 2024
Added 31.81%
|
|
| 9,373 | 0 | 9,373 $174,993 | 2 |
Jun 06, 2024
Added 31.81%
|
|
|
Qasim Rizvi
Chief Commercial Officer |
7,337 | 2,161 | 5,176 $96,635 | 2 |
Dec 31, 2020
Reduced 29.45%
|